Ogivri is named as an intervention in 3 current clinical trials in our Canada, Israel, UK, USA, Japan, South Korea and Brazil registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Merck Sharp & Dohme LLC (1). The most-studied condition is Breast Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
NCT04680442 · ClinicalTrials.gov ↗ · Breast Cancer, Heart Failure
|
Phase 2 | Recruiting | Population Health Research Institute | Canada, Brazil |
|
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT06686394 · ClinicalTrials.gov ↗ · Breast Neoplasms, Breast Cancer
|
Phase 1/2 | Recruiting | Merck Sharp & Dohme LLC | UK, USA, Canada, Japan, South Korea, Israel |
|
MARGetuximab Or Trastuzumab (MARGOT)
NCT04425018 · ClinicalTrials.gov ↗ · Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
|
Phase 2 | Active, closed | Dana-Farber Cancer Institute | Israel |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 1 |
| Population Health Research Institute | 1 |
| Dana-Farber Cancer Institute | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 2 | 2 |
| Clinical trials in Israel | 2 | 1 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in USA | 1 | 1 |
| Clinical trials in Japan | 1 | 1 |
| Clinical trials in South Korea | 1 | 1 |
| Clinical trials in Brazil | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our Canada, Israel, UK, USA, Japan, South Korea and Brazil registers name Ogivri as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 2 with sites in Canada, 1 with sites in Israel, 1 with sites in UK, 1 with sites in USA, 1 with sites in Japan, 1 with sites in South Korea and 1 with sites in Brazil. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Merck Sharp & Dohme LLC (1), Population Health Research Institute (1) and Dana-Farber Cancer Institute (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ogivri works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ogivri works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ogivri (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.